Alvotech Reports Update on Initial AVT02 Biologics License Application

September 5, 2022

https://www.globenewswire.com/news-release/2022/09/05/2509600/0/en/Alvotech-Reports-Update-on-Initial-AVT02-Biologics-License-Application.html

Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that Alvotech received communication from the U.S. Food and Drug Administration (FDA) detailing its assessment of the March 2022 inspection of Alvotech’s manufacturing facility in Reykjavik, Iceland and Alvotech’s subsequent written responses to the FDA. 

Read more at globenewswire.com

Related news for (ALVO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.